GuidelinePain research & management
Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.
Guideline in Pain research & management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07451431 (Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain), which is not on this map. Cited by 219 papers, 26 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy, Safety and Patient-Reported Outcomes of Mirogabalin in Diabetic Peripheral Neuropathic Pain
Who cites it
219 citing papers in PubMed, 26 syntheses or guidelines pooled it, 526 citations in OpenAlex.
- Pooled it
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
- Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Pooled it
- Monotherapy Versus Combination Therapy in the Treatment of Painful Diabetic Neuropathy: A Systematic Review and Meta-analysis.Clinical drug investigation · 2023Pooled it
- Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials.Systematic reviews · 2023Pooled it
- Research trends and hotspots of neuropathic pain in neurodegenerative diseases: a bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Efficacy and safety of different drug treatments in patients with spinal-cord injury-related neuropathic pain: a network meta-analysis.Spinal cord · 2022Pooled it
- Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review.Spinal cord series and cases · 2022Pooled it
- PEER systematic review of randomized controlled trials: Management of chronic neuropathic pain in primary care.Canadian family physician Medecin de famille canadien · 2021Pooled it
- Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations.Pain research & management · 2021Pooled it
- Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Pooled it
- Pooled it
- Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon.Cephalalgia : an international journal of headache · 2019Pooled it
- Pregabalin for neuropathic pain in adults.The Cochrane database of systematic reviews · 2019Pooled it
- Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials.BMJ open · 2019Pooled it
- Cannabis-based medicines for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.Canadian family physician Medecin de famille canadien · 2017Pooled it
- Cannabinoids in Pain Management and Palliative Medicine.Deutsches Arzteblatt international · 2017Pooled it
- Antidepressants for chronic non-cancer pain in children and adolescents.The Cochrane database of systematic reviews · 2017Pooled it
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropathic pain (NeP), redefined as pain caused by a lesion or a disease of the somatosensory system, is a disabling condition that affects approximately two million Canadians.
objectiveTo review the randomized controlled trials (RCTs) and systematic reviews related to the pharmacological management of NeP to develop a revised evidence-based consensus statement on its management.
methodsRCTs, systematic reviews and existing guidelines on the pharmacological management of NeP were evaluated at a consensus meeting in May 2012 and updated until September 2013. Medications were recommended in the consensus statement if their analgesic efficacy was supported by at least one methodologically sound RCT (class I or class II) showing significant benefit relative to placebo or another relevant control group. Recommendations for treatment were based on the degree of evidence of analgesic efficacy, safety and ease of use.
resultsAnalgesic agents recommended for first-line treatments are gabapentinoids (gabapentin and pregabalin), tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors. Tramadol and controlled-release opioid analgesics are recommended as second-line treatments for moderate to severe pain. Cannabinoids are now recommended as third-line treatments. Recommended fourth-line treatments include methadone, anticonvulsants with lesser evidence of efficacy (eg, lamotrigine, lacosamide), tapentadol and botulinum toxin. There is support for some analgesic combinations in selected NeP conditions.
conclusionsThese guidelines provide an updated, stepwise approach to the pharmacological management of NeP. Treatment should be individualized for each patient based on efficacy, side-effect profile and drug accessibility, including cost. Additional studies are required to examine head-to-head comparisons among analgesics, combinations of analgesics, long-term outcomes and treatment of pediatric, geriatric and central NeP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.